Related references
Note: Only part of the references are listed.Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study
Gonzalo Diaz-Soto et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
G. B. Bolli et al.
DIABETIC MEDICINE (2014)
Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer
James D. Lewis et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Lesley J. Scott
BIODRUGS (2013)
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Julio Rosenstock et al.
DIABETES CARE (2013)
Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Bo Ahren et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
M. Pinget et al.
DIABETES OBESITY & METABOLISM (2013)
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
C. Kapitza et al.
DIABETES OBESITY & METABOLISM (2013)
Potential of incretin-based therapies for non-alcoholic fatty liver disease
Susan L. Samson et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
The burden of liver disease in Europe: A review of available epidemiological data
Martin Blachier et al.
JOURNAL OF HEPATOLOGY (2013)
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia
Martin Lorenz et al.
REGULATORY PEPTIDES (2013)
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca et al.
DIABETES CARE (2012)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2012)
Statistical Analysis of Individual Participant Data Meta-Analyses: A Comparison of Methods and Recommendations for Practice
Gavin B. Stewart et al.
PLOS ONE (2012)
Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease
Neven Barsic et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Lixisenatide for type 2 diabetes mellitus
Mikkel Christensen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review
D. Shyangdan et al.
HEALTH TECHNOLOGY ASSESSMENT (2011)
Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease
Michael H. Miller et al.
LIVER INTERNATIONAL (2011)
Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease
J. M. Estep et al.
CURRENT MOLECULAR MEDICINE (2010)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
Giovanni Targher et al.
DIABETES CARE (2007)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study
G Bedogni et al.
HEPATOLOGY (2005)
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
LS Szczepaniak et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Bleeding complications after percutaneous liver biopsy
B Terjung et al.
DIGESTION (2003)
Share Paper
